Alnylam Pharmaceuticals (ALNY) Short-term Investments (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has 18 years of Short-term Investments data on file, last reported at $1.3 billion in Q1 2026.

• For the quarter ending Q1 2026, Short-term Investments rose 17933.94% year-over-year to $1.3 billion; the trailing twelve-month figure through Mar 2026 stood at $1.3 billion (up 17933.94% YoY), and the FY2025 full-year result was $1.3 billion, up 15241.27% from the prior year.
• Short-term Investments for Q1 2026 stood at $1.3 billion, up from $1.3 billion in the prior quarter.
• Across five years, Short-term Investments topped out at $1.7 billion in Q2 2025 and bottomed at $7.2 million in Q1 2025.
• The 5-year median for Short-term Investments is $1.3 billion (2026), against an average of $1.0 billion.
• The widest annual swing landed in 2025, when Short-term Investments plunged 99.57%; it then surged 17933.94% in 2026.
• A 5-year view of Short-term Investments shows it stood at $28.1 million in 2022, then jumped by 5644.67% to $1.6 billion in 2023, then slumped by 99.5% to $8.2 million in 2024, then surged by 15241.27% to $1.3 billion in 2025, then increased by 3.77% to $1.3 billion in 2026.
• The last three Short-term Investments figures came in at $1.3 billion (Q1 2026), $1.3 billion (Q4 2025), and $1.2 billion (Q3 2025), per Business Quant data.

Peer Comparison